Skip to content
DraconiticResearch
Search Sources API
189,105 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Clinical translation of liquid biopsy in early cancer screening: biofluid selection, model construction, and clinical validation

  • Pin Cui1
  • Shu Xu2
  • Xiaohui Lin3
  • Shiyi Song4
  • Bingding Huang5
  • Zhiming Xu2
5 affiliations
  1. 1Shenzhen Rapha Biotechnology Inc.
  2. 2Cancer Center, Shenzhen University of Advanced Technology General Hospital
  3. 3Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal, Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital
  4. 4Department of Endoscopy, The First Affiliated Hospital of Henan Medical University, and Henan Key Laboratory of the Prevention and Treatment of Gastrointestinal Cancer
  5. 5School of Artificial Intelligence, Shenzhen Technology University
Open at sourcePDFDOICite

Abstract

Global cancer incidence continues to rise, underscoring the urgent need for effective early detection strategies. Liquid biopsy shows promise as a minimally invasive approach, yet only a limited number of assays have successfully transitioned from research to clinical practice. This review examines the critical decisions and challenges encountered along the translational pathway for liquid biopsy based early cancer screening, covering biofluid selection, biomarker characteristics, multi-omics integration, model construction, and the hierarchy of clinical evidence. We highlight the importance of biologically driven complementarity in biomarker combination, rigorous control group design, and prospective real-world validation, while also identifying key gaps that currently constrain clinical adoption. Collectively, these considerations aim to inform more efficient development strategies and help bridge the gap between technological innovation and clinically impactful tests.

Related

  1. Construction and validation of a frailty screening model for older adults with cataract: a cross-sectional study
    Xingdong Cheng, Heting Liang, Qingyun Mao +4
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. From wrist to heart: clinical validation and real-world translation of wearable and portable AI-enhanced electrocardiography
    European heart journal. Digital healthPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Deep-Learning-Based Assessment of Breast Arterial Calcification on Mammography: Technical Validation, Cardiovascular Prognostic Value, and Clinical Translation—A Narrative Review
    Alexandru Carauleanu, Amelian M. Bobu, Elena Porumb-Andrese +8
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Artificial Intelligence in Endoscopic Ultrasonography for Gastrointestinal Subepithelial Lesions: Evidence, Validation, and Clinical Translation
    Elettra Merola, Leonardo Sosa-Valencia, Andrea Michielan +4
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  5. Assessing coercive control in intimate partner relationships: psychometric validation and clinical thresholds of a French version of the Coercive Control Screening Scale (CCSS-F)
    Fatima Le Griguer Atig, Corentin Gonthier, Tabatha Magagna +5
    European Journal of PsychotraumatologyPeer-reviewedCC BY-ND 4.0Full textNeurosciencePsychiatry & mental healthHAL

Cite

BibTeXRIS
BibTeX
@article{cui2026clinical,
  title = {{Clinical translation of liquid biopsy in early cancer screening: biofluid selection, model construction, and clinical validation}},
  author = {Pin Cui and Shu Xu and Xiaohui Lin and Shiyi Song and Bingding Huang and Zhiming Xu},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1946352},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1946352/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Clinical translation of liquid biopsy in early cancer screening: biofluid selection, model construction, and clinical validation
AU  - Pin Cui
AU  - Shu Xu
AU  - Xiaohui Lin
AU  - Shiyi Song
AU  - Bingding Huang
AU  - Zhiming Xu
PY  - 2026
DA  - 2026/10/26
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1946352
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1946352/full
AB  - Global cancer incidence continues to rise, underscoring the urgent need for effective early detection strategies. Liquid biopsy shows promise as a minimally invasive approach, yet only a limited number of assays have successfully transitioned from research to clinical practice. This review examines the critical decisions and challenges encountered along the translational pathway for liquid biopsy based early cancer screening, covering biofluid selection, biomarker characteristics, multi-omics integration, model construction, and the hierarchy of clinical evidence. We highlight the importance of biologically driven complementarity in biomarker combination, rigorous control group design, and prospective real-world validation, while also identifying key gaps that currently constrain clinical adoption. Collectively, these considerations aim to inform more efficient development strategies and help bridge the gap between technological innovation and clinically impactful tests.
SN  - 2234-943X
ER  -